ClinicalTrials.gov
public full text
Public Domain
FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib
The goal of this clinical research study is to learn if an imaging solution, \[F-18\]-fluoro-L-thymidine (FLT), when used with a positron emission tomography (PET) scan, can help doctors to better see changes in the growth of tumors in the body. Researchers want to learn if FLT-PET scans can show an early response to chemotherapy.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer#829464
- [18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer#833202
- FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents#902379
- Fluorine F 18 EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Cervical Cancer#1444034
- Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy#1375750
Record · ID 1463808
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive